| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
48,350,000 |
| Market
Cap: |
63.34(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.68 - $2.02 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 9.3 |
| Insider 6 Months : 12.9 |
| Insider 3/6 Months : 22.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Clearside Biomedical is a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS). Co.'s SCS injection platform, utilizing its SCS Microinjector, enables non-surgical procedure for the targeted delivery of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. Co. is utilizing its SCS injection platform by building a research and development pipeline targeting retinal diseases and by creating external collaborations with other companies. Co.'s product is XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in therapy for macular edema.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
137,813 |
582,257 |
738,035 |
782,035 |
| Total Buy Value |
$187,900 |
$787,899 |
$904,948 |
$959,114 |
| Total People Bought |
3 |
4 |
6 |
6 |
| Total Buy Transactions |
4 |
5 |
10 |
12 |
| Total Shares Sold |
0 |
30,900 |
30,900 |
80,830 |
| Total Sell Value |
$0 |
$39,372 |
$39,372 |
$113,315 |
| Total People Sold |
0 |
2 |
2 |
3 |
| Total Sell Transactions |
0 |
2 |
2 |
6 |
| End Date |
2024-02-17 |
2023-11-16 |
2023-05-18 |
2022-05-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yerxa Benjamin R |
Director |
– • – |
2022-03-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,144 |
|
15% |
|
| Ciulla Thomas |
Chief Medical Officer |
• – – |
2022-01-19 |
4 |
AS |
$2.13 |
$19,277 |
D/D |
(9,050) |
295,260 |
|
-36% |
|
| Deignan Charles A. |
Chief Financial Officer |
• – – |
2022-01-19 |
4 |
AS |
$2.09 |
$18,461 |
D/D |
(8,833) |
351,366 |
|
-36% |
|
| Lasezkay George M |
CEO |
• • – |
2022-01-19 |
4 |
AS |
$2.12 |
$22,896 |
D/D |
(10,800) |
504,607 |
|
-36% |
|
| Deignan Charles A. |
Chief Financial Officer |
• – – |
2022-01-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
46,250 |
362,699 |
|
- |
|
| Ciulla Thomas |
Chief Medical Officer |
• – – |
2022-01-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
46,250 |
301,810 |
|
- |
|
| Ciulla Thomas |
Chief Medical Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
299,310 |
|
- |
|
| Deignan Charles A. |
Chief Financial Officer |
• – – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
360,199 |
|
- |
|
| Lasezkay George M |
CEO |
• • – |
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
97,500 |
515,407 |
|
- |
|
| Lasezkay George M |
CEO |
• • – |
2022-01-11 |
4 |
AS |
$2.46 |
$12,546 |
D/D |
(5,100) |
417,907 |
|
-44% |
|
| Humphries William D. |
Director |
– • – |
2022-01-10 |
4 |
OE |
$0.15 |
$3,409 |
D/D |
22,727 |
28,313 |
|
- |
|
| Hutson Nancy J |
Director |
– • – |
2021-10-29 |
4 |
OE |
$2.00 |
$81,350 |
D/D |
40,000 |
53,000 |
|
- |
|
| Deignan Charles A. |
Chief Financial Officer |
• – – |
2021-09-21 |
4 |
AS |
$6.41 |
$17,948 |
D/D |
(2,800) |
316,449 |
|
-70% |
|
| Lasezkay George M |
CEO |
• • – |
2021-09-21 |
4 |
AS |
$6.46 |
$22,772 |
D/D |
(3,525) |
423,007 |
|
-70% |
|
| Ciulla Thomas |
Chief Medical Officer |
• – – |
2021-09-21 |
4 |
AS |
$6.40 |
$16,384 |
D/D |
(2,560) |
255,560 |
|
-70% |
|
| Whitmore Bradford T |
10% Owner |
– – • |
2021-09-01 |
4 |
S |
$6.89 |
$1,469,246 |
I/I |
(213,203) |
2,415,056 |
|
65% |
|
| Whitmore Bradford T |
10% Owner |
– – • |
2021-08-31 |
4 |
S |
$6.96 |
$749,079 |
I/I |
(107,682) |
2,628,259 |
|
64% |
|
| Whitmore Bradford T |
10% Owner |
– – • |
2021-08-30 |
4 |
S |
$7.06 |
$702,102 |
I/I |
(99,400) |
2,735,941 |
|
65% |
|
| Hutson Nancy J |
Director |
– • – |
2021-08-16 |
4 |
B |
$5.68 |
$17,040 |
D/D |
3,000 |
13,000 |
2.39 |
-50% |
|
| Deignan Charles A. |
Chief Financial Officer |
• – – |
2021-06-21 |
4 |
AS |
$4.37 |
$12,839 |
D/D |
(2,938) |
319,249 |
|
17% |
|
| Lasezkay George M |
CEO |
• • – |
2021-06-21 |
4 |
AS |
$4.38 |
$16,237 |
D/D |
(3,707) |
426,532 |
|
17% |
|
| Lasezkay George M |
CEO |
• • – |
2021-03-19 |
4 |
AS |
$2.82 |
$9,503 |
D/D |
(3,370) |
430,239 |
|
90% |
|
| Hutson Nancy J |
Director |
– • – |
2021-03-12 |
4 |
B |
$3.11 |
$15,525 |
D/D |
5,000 |
10,000 |
2.39 |
76% |
|
| Lasezkay George M |
CEO |
• • – |
2021-03-02 |
4 |
AS |
$3.37 |
$20,220 |
D/D |
(6,000) |
433,609 |
|
69% |
|
| Thorp Clay |
Director |
– • – |
2021-02-10 |
4/A |
AS |
$4.43 |
$145,627 |
D/D |
(32,873) |
4,951,547 |
|
- |
|
195 Records found
|
|
Page 2 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.76%) 
